Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that PI3K/AKT mutations may not play a major role in multiple myeloma.
|
20022634 |
2010 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
2,4-Dihydroxy-3'-methoxy-4'-ethoxychalcone suppresses cell proliferation and induces apoptosis of multiple myeloma <i>via</i> the PI3K/akt/mTOR signaling pathway.
|
31564190 |
2019 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings indicated the critical roles of ABCG2 and PI3K/AKT signaling in controlling stemness of MM cells, and suggested a novel strategy for targeting ABCG2 and PI3K/AKT signaling to treat MM with MDR.
|
30664164 |
2019 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Noteworthy, the results of the synergistic experiments also revealed that BKM120 could produce a synergistic anti-cancer effect with carfilzomib (CFZ) and provided an enhanced therapeutic efficacy in MM cells, highlighting that PI3K inhibition might be a befitting approach in MM both in mono and combined therapy.
|
30401630 |
2019 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The PI3K/Akt/mTOR signal transduction pathway plays a central role in multiple myeloma (MM) disease progression and development of therapeutic resistance. mTORC1 inhibitors have shown limited efficacy in the clinic, largely attributed to the reactivation of Akt due to rapamycin induced mTORC2 activity.
|
23185517 |
2012 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report that PI3Kδ and PI3Kγ isoforms have distinct functions in MM and that combined PI3kδ/γ isoform inhibition has anti-MM activity.
|
28282033 |
2017 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results collectively demonstrate that acid activates the TRPV1-PI3K-Akt-Sp1 signaling in MM cells while inducing HDAC-mediated gene repression, and suggest that a positive feedback loop between acid sensing and the PI3K-Akt signaling is formed in MM cells, leading to MM cell response to acidic bone lesions.
|
27626482 |
2016 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, our results demonstrated that the enforced expression of miR-145 in H929 cells profoundly decreased the levels of p-AKT and p-PI3K, which may contribute to some extent to the inhibition of MM cell proliferation and survival.
|
25369735 |
2015 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Concomitant pan-Raf/PI3K inhibition was also effective in carfilzomib- and lenalidomide-resistant MM models underscoring that this attractive therapeutic anti-MM strategy is suitable for immediate clinical translation.
|
27686868 |
2017 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We show p110 α and β are the predominant PI3K catalytic subunits in MM and that a highly selective class I PI3K inhibitor, GDC-0941, has robust activity as a single agent to induce cell cycle arrest and apoptosis of both MM cell lines and patient myeloma cells.
|
23318440 |
2014 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Both the ubiquitin proteasome system (UPS) and the PI3K/Akt/mTOR signaling pathways have been implicated in the pathogenesis, and treatment of MM and different lines of evidence suggest a close cross talk between these central cell-regulatory signaling networks.
|
30712673 |
2019 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) is such a pathway that is aberrantly activated in a large proportion of MM patients through numerous mechanisms and can play a role in resistance to several existing therapies making this a central pathway in MM pathophysiology.
|
29322846 |
2018 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, the novel specific PI3K/Akt/mTOR signaling inhibitor S14161 displayed its prowess as a potential therapeutic agent by targeting MM SP cells.
|
25915427 |
2015 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that oncogenic RAS is a predictor of sensitivity to combination treatment with PI3K/Akt and MEK/MAPK inhibitors and that such an approach might therefore be beneficial for this genetically well-defined subgroup of MM patients.
|
22985491 |
2012 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we investigated the effect of miR-20a on the PTEN/PI3K/Akt signaling pathway during MM cell proliferation, migration and apoptosis.
|
29963125 |
2018 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, bortezomib activates the phosphatidylinositol 3-kinase/AKT (PI3K/AKT) pathway (which is essential to the development of myeloma), often resulting in drug resistance and disease recurrence.
|
27439454 |
2017 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma.
|
28350342 |
2017 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A previous study indicated that BENC-511 acted on multiple myeloma and that it had a toxicity by inhibiting the PI3K/protein kinase B (Akt) pathway.
|
30867372 |
2019 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, our results have established the role of PTEN, but not SHIP and SHIP2, in negatively regulating the PI3K/Akt cascade and in myeloma leukemogenesis.
|
12149650 |
2002 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have identified a robust cytogenetic biomarker for response to PI3K/mTOR inhibition--these results will inform the design and prioritisation of clinical studies with novel inhibitors in genetic subgroups of myeloma.
|
22415553 |
2012 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PI3K/p110{delta} is a novel therapeutic target in multiple myeloma.
|
20505158 |
2010 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The PI3K/mTOR/AKT pathway is an integral regulator of survival and drug resistance in multiple myeloma (MM).
|
29254208 |
2017 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The PI3K/Akt/mTOR pathway is constitutively activated in human multiple myeloma (MM) cell lines and in freshly isolated plasmocytes from patients with MM.
|
30787971 |
2019 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Endoplasmic reticulum stress induces autophagy and apoptosis while inhibiting proliferation and drug resistance in multiple myeloma through the PI3K/Akt/mTOR signaling pathway.
|
28977849 |
2017 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Pim inhibitor (Z)-5-(4-propoxybenzylidene) thiazolidine-2, 4-dione and the PI3K inhibitor LY294002 cooperatively enhance MM cell death.
|
21475253 |
2011 |